In this episode of the Oncology Brothers, we welcomed Dr. Suneel Kamath from the Cleveland Clinic to discuss the complex landscape of biliary tract cancer. While this cancer type is not the most common, it carries a poor prognosis, making it crucial for oncologists to stay informed about the latest treatment options.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• ⁠X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Join us as we explored:

• The role of surgery and adjuvant chemotherapy in early-stage biliary tract cancer.
• Frontline treatment strategies for metastatic disease, including insights from the TOPAZ-1 and KEYNOTE-966 studies.
• The importance of biomarker testing, including HER2, IDH1, and FGFR mutations, and how they influence treatment decisions.
• Management of side effects associated with various therapies, including immunotherapy and chemotherapy.
• The emerging landscape of targeted therapies and the need for more effective treatment options.

Whether you're a medical professional or someone interested in oncology, this episode provides valuable insights into the current treatment algorithms and challenges in managing biliary tract cancer.

Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!

#BiliaryTractCancer, #Cholangiocarcinoma, #Immunotherapy, #BiomarkerTesting, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of Cancer of Unknown Primary (CUP). Joined by Dr. Harry Fuentes Bayne and Dr. Thor Halfdanarson from the Mayo Clinic, they discussed the current standard of care, diagnostic workup, and treatment options for this challenging condition.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Key topics included:

• Initial diagnostic approaches for CUP, including imaging and tissue sampling
• The role of immunohistochemistry (IHC) and tumor markers in guiding treatment
• The use of next-generation sequencing (NGS) and tools like Cancer Type ID
• Treatment strategies, including chemotherapy regimens and the potential for immunotherapy
• The importance of thorough workup and palliative care in managing CUP

Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the latest approaches for diagnosing and treating cancer of unknown primary origin.

Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and FDA approvals. Join us on this journey through the world of oncology!

#CancerOfUnknownPrimary, #CUP, #NGS, #Immunohistochemistry, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving treatment algorithms for bladder cancer following the latest data presented at GU ASCO 2026.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Join us as we explore:

• The role of immunotherapy in non-muscle invasive bladder cancer, highlighting the recent positive trials: CREST with Sasanlimab and POTOMAC with Durvalumab.
• Insights on the current standard of care and the implications of combining BCG with immunotherapy.
• The shift in treatment strategies for muscle-invasive bladder cancer, including the new standard of care with the EV-Pembro combination and its impact on pathologic complete response rates.
• The challenges and considerations in managing side effects associated with new therapies, as well as the importance of patient selection and coordination between urologists and medical oncologists.
• The emerging role of ctDNA in guiding treatment decisions and the ongoing discussions around the sequencing of therapies in refractory settings.

Hope you enjoy this informative discussion that aims to keep you up to date in the world of cancer treatment, here focusing on bladder cancer.

Subscribe to our channel for more episodes and discussions on the latest in oncology!

#BladderCancer, #NMIBC, #MIBC, #Immunotherapy, #GU26, #OncologyBrothers